A Lyon startup just banked $38 million on a counterintuitive wager: that the future of dairy protein isn't about replicating what cows produce, but engineering something they can't.
Verley—which shed its earlier name, Bon Vivant, in a March 2025 rebrand that signaled ambitions beyond European artisanal markets—announced its Series A in late February from Alven, with Blast and state-backed Bpifrance joining. The round lands as precision-fermented dairy proteins, a market worth barely $100 million in 2024, barrels toward a projected $1 billion by 2034. That's 24.3% compounded annual growth, the kind of trajectory that reflects more than investor optimism. It suggests the architecture of protein supply chains is being rewritten.
What makes Verley's raise notable isn't the size—$38 million is substantial but not extraordinary in European deep tech. It's the timing and the technical claim. Three months before closing, in October 2025, the FDA issued "No Questions" letters for two of Verley's whey protein products: FermWhey Native and FermWhey MicroStab. The company insists this marks the first FDA acknowledgment of functionalized precision-fermented whey—proteins brewed in steel tanks by engineered microbes, then modified through proprietary processing to outperform the dairy versions they're modeled on.
Whether that distinction holds up under scrutiny matters considerably. In a sector where regulatory clearance remains the chokepoint between laboratory curiosity and commercial ingredient, "first functionalized FDA clearance" is the kind of claim that shapes fundraising decks and partnership negotiations.
Beyond Molecular Mimicry
Most precision fermentation startups have pursued a straightforward playbook: code the gene for a dairy protein into yeast or bacteria, ferment at scale, isolate the protein, sell it as a drop-in replacement for its animal-derived twin. Same amino acid sequence, same nutritional profile, theoretically same performance. Lower environmental footprint.
Verley's founders—chief technology officer Hélène Briand and CEO Stéphane Mac Millan—are pushing past the drop-in model. Their pitch centers on post-fermentation processing that creates functional properties conventional dairy proteins can't easily deliver. Take MicroStab, which gets microparticulated to survive ultra-high-temperature processing and remain stable in acidic drinks. That opens applications in shelf-stable protein shots and clear sports beverages, categories where standard whey concentrates tend to precipitate into cloudy, unappetizing suspensions.
Or FermWhey Gel, engineered for cold-gelling behavior in clean-label yogurts and spoonable formats. The company has filed U.S. patent applications covering what it calls its MicroFactor and GelFactor platforms. The message is unambiguous: Verley sees intellectual property around functionality, not just molecular identity, as its competitive moat.
"We're not trying to be dairy," Briand told industry audiences at VivaTech 2025, where she won the Female Founder Challenge. "We're trying to be what formulators actually need dairy to be."
That distinction—complement rather than replace—has become something of a sector mantra, though whether it reflects genuine philosophy or savvy positioning is open to interpretation. Either way, it aligns with what's increasingly pragmatic: precision fermentation works best when it augments conventional agriculture rather than declaring war on it.
The Environmental Math
The sustainability case feels almost perfunctory at this point. A life cycle assessment commissioned by Verley reports 72% lower greenhouse gas emissions, 81% less water use, and 99% less land compared to conventional dairy for equivalent protein output. Those figures track broadly with industry benchmarks. Perfect Day, the California pioneer that secured FDA clearance back in 2020, has published LCAs claiming up to 97% lower GHG emissions for its whey protein.
Still, the numbers merit skepticism—or at least context.
An independent 2022 academic study published in Springer noted that precision-fermented milk protein carbon footprints range from 5.5 to 17.6 tonnes CO₂-equivalent per tonne of protein, better than conventional dairy but with significant variation depending on energy sources and system boundaries. Perfect Day's figures assume renewable energy. Run the same fermentation on a coal-heavy grid and the advantage narrows considerably.
The FAO pegs dairy's contribution to global anthropogenic greenhouse gases at around 2.7% for milk production alone. Even conservative reductions matter at scale, but the sector's environmental claims are only as reliable as the assumptions baked into them. Energy procurement will determine whether fermentation becomes a genuine climate solution or just a lower-carbon alternative that still requires substantial grid decarbonization to deliver on its promise.
A Market Finding Its Footing
The precision fermentation dairy space has moved from proof-of-concept to industrial buildout faster than most forecasts anticipated. At least 17 fermentation facilities opened or were announced in 2024 across various subcategories, according to the Good Food Institute's State of the Industry report. In the first half of 2024 alone, European precision fermentation startups raised more than €49 million, part of a broader €164 million invested in fermentation technologies during that period.
Capital is flowing toward fermentation over plant-based proteins and cultivated meat, at least in the near term. The reasons aren't mysterious. Fermentation leverages established industrial biotechnology infrastructure. It doesn't require bioreactors the size of city blocks or trillion-dollar tissue engineering breakthroughs. And crucially, it produces actual dairy proteins—beta-lactoglobulin, casein, lactoferrin—not approximations.
Regulatory momentum is building, particularly in the U.S. Israel's Imagindairy and Remilk, the Netherlands' Vivici, and Singapore-U.S. hybrid TurtleTree have all secured FDA clearances for beta-lactoglobulin or lactoferrin since Perfect Day's 2020 letter. Canada's Health Canada issued a "letter of no objection" for Remilk's BLG in 2024. Israel and Singapore have granted domestic approvals for multiple precision-fermented dairy proteins.
Europe? That's where things get complicated.
Precision-fermented dairy proteins require European Food Safety Authority Novel Food authorization before they can enter EU retail. The EU Biotech Act, passed in December 2025, expanded pre-submission guidance but explicitly excluded novel foods from regulatory sandboxes. Several companies are pursuing EU dossiers. Timelines remain uncertain, sometimes stretching into years.
The result is a bifurcated market: North America and select Asian jurisdictions where products are already reaching consumers, and Europe where capacity is growing but market access lags. For a region that prides itself on sustainability leadership, the irony isn't lost on anyone.
Where the Demand Actually Is
Adoption so far is concentrated in B2B ingredients rather than branded consumer products. Unilever's Breyers launched a lactose-free chocolate ice cream with Perfect Day whey in 2024. Bored Cow, a milk brand using Perfect Day's proteins, expanded to Target and over 3,400 U.S. stores that same year.
But the real volume opportunity appears to be in performance nutrition—protein powders, ready-to-drink shakes, medical nutrition formulas. And increasingly, companion products for GLP-1 users who need high-quality protein to preserve lean mass during weight loss. Verley's leadership has cited GLP-1-driven protein demand as a key rationale for its functionalized whey strategy, a nod to how obesity pharmacology is reshaping nutritional product development.
FermWhey Native 100, for example, boasts greater than 95% purity and solubility in clear, acidic beverages—a format where conventional whey concentrates often precipitate. That's a technical unlock for a category (clear protein waters, lemonades, teas) that has grown rapidly but struggled with protein inclusion. Performance matters as much as sustainability when you're pitching to beverage formulators.
Three Forces Accelerating Maturation
The sector's evolution is being driven by technological, economic, and infrastructural shifts that are converging with unusual speed.
First, the shift from simply replicating native dairy proteins to engineering them for superior functionality. Verley's MicroStab and Gel products represent this trend, but they're not alone. New Culture, a U.S. casein startup, reported in late 2024 that it had reduced casein inclusion in its mozzarella by roughly 28% while maintaining full functionality, with more than $5 million in pre-launch demand from pizzerias. That's not just sustainability—it's cost engineering and performance optimization bundled into the same R&D effort.
Second, circular economics. France's Standing Ovation and Bel Group validated industrial-scale production of precision-fermented casein from acid whey—a low-value byproduct of cheese manufacturing—in October 2025. The partnership converts waste streams into high-value protein ingredients, a model that could reshape both the economics and the sustainability narrative of fermentation.
If precision fermentation can valorize dairy side streams rather than displace dairy entirely, it becomes complementary. That framing eases incumbent anxiety and opens co-investment opportunities. It's also, perhaps, more honest about how the technology will actually get deployed.
Third, infrastructure. Capacity remains a constraint, particularly in Europe. Liberation Labs, a U.S.-based biomanufacturing platform, is receiving backing from Saudi Arabia's NEOM Investment Fund to build precision fermentation capacity in the Kingdom. Remilk is advancing a large facility in Kalundborg, Denmark. Germany's Formo secured a €35 million quasi-equity loan from the European Investment Bank in January 2025 to scale animal-free cheese production.
These are not lab projects. They are industrial-scale capital commitments.
The Regulatory Wild Card
Regulation is both enabler and bottleneck, accelerating some markets while strangling others.
The FDA's GRAS (Generally Recognized as Safe) self-affirmation pathway, followed by "no questions" letters, has proven faster than EU Novel Food authorization. But that speed comes with scrutiny. An NGO filed suit against Perfect Day in 2024 over "animal-free" and "identical" marketing claims, arguing that analytical differences exist between precision-fermented and animal-derived proteins.
The outcome of that litigation could shape labeling guidance industry-wide. It will certainly set precedents for how "identity" claims are substantiated. Will products carry "whey protein from fermentation," "animal-free whey," "recombinant whey," or simply "whey protein"? The industry has yet to converge on terminology. Clarity won't come quickly.
The Bellwether and Its Rivals
Perfect Day remains the sector's bellwether, for better or worse. Its partnerships with Unilever and Tomorrow Farms (Bored Cow) demonstrate consumer product validation, but the company has pivoted increasingly toward ingredient licensing rather than branded goods. Its LCA data—up to 97% lower GHG emissions, 96-99% less blue water, and 29-60% less non-renewable energy versus conventional whey—set early benchmarks, though methodological debates persist.
Imagindairy, an Israeli startup, received FDA clearance for its BLG protein in early 2024 and subsequently acquired over 100,000 liters of fermentation capacity to reach industrial scale. The company is targeting cost parity with conventional whey protein isolates, a milestone that remains aspirational across the sector.
Remilk has secured regulatory approvals in the U.S., Canada, Singapore, and Israel, and is advancing its Denmark facility to serve European markets pending Novel Food authorization. On the casein side, New Culture's mozzarella with roughly half the casein content of dairy cheese represents a different kind of innovation—less protein, same function, lower cost.
These aren't just climate plays. They are margin plays, efficiency plays, supply chain resiliency plays. The companies that succeed will be those that deliver on all three simultaneously.
The Bifurcation Ahead
The precision-fermented dairy proteins market will likely split over the next two to three years.
One segment will chase cost parity with commodity dairy proteins—whey concentrates, caseinates—and compete on sustainability credentials in high-volume applications like protein bars, shakes, and baked goods. Success here depends on fermentation yield optimization, feedstock costs, and energy procurement. It's a volume game with slim margins.
The second segment will pursue premium functionality—UHT stability, acid solubility, novel textures—and command higher margins in performance nutrition, medical foods, and specialized beverage formats. Verley is clearly betting on the latter. Whether that bet pays off depends on whether formulators value those functional improvements enough to absorb price premiums during scale-up.
Regulatory cadence will shape commercialization timelines in ways that may prove more decisive than technology. More FDA "no questions" letters are expected in 2026 for additional dairy sub-fractions—alpha-lactalbumin, lactoferrin, specific casein fractions. The EU Novel Food queue remains the critical path to European retail. Companies with U.S. market access will scale first; those locked out of Europe may look to Middle Eastern capacity and export markets.
Consumer acceptance is harder to predict, and perhaps harder to engineer. EIT Food and HealthFerm data suggest 43-52% of European consumers are willing to try precision-fermented foods, but willingness collapses when price premiums exceed roughly 10-15% versus conventional equivalents. That's a narrow window, and it won't stay open indefinitely.
What Remains to Be Proven
Verley's Series A—and the FDA clearance preceding it—suggest investors believe the sector is crossing from venture-backed curiosity to genuine industrial category. The momentum is real. The infrastructure is being built. The regulatory pathways are opening, however unevenly.
But the margins remain to be proven.
If precision fermentation dairy proteins reach even the low end of forecast growth—approaching $1 billion by 2034—they will represent a meaningful ingredient market, not a niche wellness trend. The question isn't whether animal-free dairy proteins have a market. It's how large that market becomes, how fast, and who captures the value as it scales.
For now, at least, the French are positioning themselves to find out. Whether Verley's functionalized whey proves superior to what cows produce will be determined not in laboratories or regulatory filings, but in the purchase orders from formulators who need proteins that work better, cost less, and don't wreck the climate.
That's a more complex value proposition than "animal-free." It's also, quite possibly, a more durable one.
